Cancer Chemotherapy and Selective Drug Development: Proceedings of the 10th Anniversary Meeting of the Coordinating Committee for Human Tumour Investigations, Brighton, England, October 24–28, 1983

Front Cover
Springer Science & Business Media, Dec 6, 2012 - Medical - 585 pages
Over the past 30 years many significant advances have been made in the management of a number of disseminated malignant diseases. The prognosis for diseases such as childhood leukaemia, choriocarcinoma and Hodgkin's disease has gradually been transformed as better anti tumour agents have become available and their clinical use has been refined. During the past 10 years the advent of new agents, particularly cisplatin, bleomycin and the podophyllotoxins, has allowed the cure of disseminated testicular tumours. This degree of success has not, however, been achieved in the case of a number of other common cancers. Ovarian carcinoma is tantalisingly chemo-sensitive and although there are long term survivors from disseminated disease, these are only a small proportion of the total. Breast cancer, although "sensitive" to a multitude of drugs appears to have yielded neither survival benefit, nor cure to the efforts of therapists, while tumours such as those of the colon remain stubbornly unresponsive. Against this backcloth it is apparent that additional more selective treatments are needed if further impact is to be made on the problem of cancer. The development of such agents requires the integration of a multidisciplinary effort encompassing the fields of chemistry, biology and medicine. This symposium provided a forum for clinical and preclinical sCientists, where current aspects of cancer treatment were reviewed and approaches to the development of a new generation of more selective anticancer drugs discussed.
 

Contents

Clinical drug resistance
5
New therapies with old drugs
13
Mismatched bone marrow transplantation
33
Prospects for immunotherapy
43
A promising new agent for the treatment of human
55
Current clinical progress podophyllotoxins
65
alkylating agents
77
Interferon
83
Antibodytoxin conjugates as anticancer agents
263
Biological response modifiers as anticancer agents
271
Prostaglandins and cancer therapeutic potential
277
The interleukins
289
Polyamines immune response and tumour growth control
301
Inosine 5phosphate dehydrogenase as a target for cancer
315
Antitumour activity and pharmacology of CCRG 81010
321
Lipophilic inhibitors of dihydrofolate reductase
333

Chemotherapy of lung cancer
91
Chemotherapy of ovarian cancer
105
Treatment of disseminated malignant lymphoma
117
Malignant disease in childhood
123
Chemotherapy of disseminated testicular cancer
135
Effective use of narcotic analgesics
147
Nonnarcotics and coanalgesics
159
Why do cancer patients vomit?
173
The medical management of malignant bowel obstruction
183
Etiology of chemotherapyinduced vomiting
189
The management of nausea and vomiting caused by anticancer
195
Experimental models and their predictive value in new drug
209
In vivo antitumour models and drug development
215
Mechanisms of resistance to anticancer agents
227
Novel structures in development
235
Induction of cell differentiation as a target for cancer therapy
251
New developments in anthracyclines
345
Further objectives in the development of platinum drugs
357
The structure of active genes and HMG proteins in normal
365
Structural requirements for DNA intercalation and their
377
DNA repair characteristics of Walker rat carcinoma cells
389
Is alkylating agent priming a DNA repair phenomenon?
395
DTIC induces damage in melanoma DNA during semiconservative
401
Alkylating antitumour agents decrease histone acetylation
413
Cytotoxicity of a steroidlinked mustard Estramustine through
425
Adjuvant tamoxifen treatment in operable breast cancer Should
439
Adjuvant hormonal therapy of breast cancer
445
The pharmacology of a new antiestrogen
457
Tissue distribution and myelotoxicity of daunomycin in normal
546
AUTHOR INDEX
583
Copyright

Other editions - View all

Common terms and phrases

Bibliographic information